Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Research & Development (2016 - 2025)

Coherus Oncology's Research & Development history spans 13 years, with the latest figure at $31.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 56.97% year-over-year to $31.0 million; the TTM value through Dec 2025 reached $108.9 million, up 18.15%, while the annual FY2025 figure was $108.9 million, 18.57% up from the prior year.
  • Research & Development for Q4 2025 was $31.0 million at Coherus Oncology, up from $27.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $246.8 million in Q2 2021 and bottomed at $11.5 million in Q1 2021.
  • The 5-year median for Research & Development is $27.8 million (2024), against an average of $43.6 million.
  • The largest annual shift saw Research & Development surged 842.8% in 2021 before it crashed 83.14% in 2022.
  • A 5-year view of Research & Development shows it stood at $50.8 million in 2021, then tumbled by 42.83% to $29.0 million in 2022, then decreased by 9.14% to $26.4 million in 2023, then decreased by 25.17% to $19.7 million in 2024, then soared by 56.97% to $31.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Research & Development are $31.0 million (Q4 2025), $27.3 million (Q3 2025), and $26.3 million (Q2 2025).